First published 9/29/2026, 6:40:15 AM · Last updated 9/29/2026, 6:40:15 AM

The role of sitagliptin in modifying metabolic, hormonal and clinical parameters in polycystic ovarian syndrome patients: a randomized controlled trial

A randomized controlled trial assessed sitagliptin's effects on metabolic, hormonal, and clinical parameters in patients with polycystic ovary syndrome; the item is a journal article published by Frontiers Media SA on 2026-09-29. No trial results, sample size, or location details are included in the supplied record.

Categories: public-health, science-and-space

Generated scores

Scores are based on the cited reporting and use a 1–10 scale. Read the methodology.

Confidence: 6/10How certain the assessment is based on the clarity and evidence in the cited reporting.
Geographic reach: 1/10How widely the event reaches, from a local area (1) to worldwide impact (10).
Global importance: 3/10The event's broader significance, from limited importance (1) to major global importance (10).
Impact magnitude: 3/10The scale or severity of the real-world impact, from minor (1) to extreme (10).
Positivity: 6/10How harmful or beneficial the event is, from strongly harmful (1) to strongly positive (10).
Urgency: 2/10How time-sensitive the event is, from low urgency (1) to immediate attention needed (10).

Why it matters

Randomized trials can provide evidence relevant to treatment decisions for people with PCOS.

Sources

The role of sitagliptin in modifying metabolic, hormonal and clinical parameters in polycystic ovarian syndrome patients: a randomized controlled trial

Report an issue